ClinicalTrials.gg

Program

cagrilintide

Also written as “Cagrilintide”, “NNC0174-0833” and “CagriSema”.

In Novo Nordisk's own words, CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hypertension · Renal Insufficiency, Chronic · Cardiovascular Diseases, led by Novo Nordisk.

Furthest: phase 3, since May 24, 202250 company-led studies, 18 open or runningNext primary completion: Mar 1, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk5018 open or runningphase 3since May 24, 2022Nov 21, 2014Mar 1, 2027phase 3 · NCT07011667
  • Named in Novo Nordisk’s own pipeline as Cagrilintide, phase 3, as of Nov 5, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Nov 21, 2014.

  1. May 30, 2025Phase 1 study in ObesityNCT07010432 · 144 planned · Denmark
  2. Jun 1, 2025Phase 3 study in ObesityNCT07011667 · 609 enrolled · United States
  3. Sep 13, 2025Phase 1 study in ObesityNCT07184086 · 80 enrolled · United States
  4. Oct 23, 20252 phase 3 studiesNCT07220759, NCT07220642
  5. Nov 19, 2025Phase 3 study in OverweightNCT07253285 · 460 planned · United States, Australia, Austria and more
  6. Dec 5, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07282613 · 80 planned · United States, Argentina, Brazil and more
  7. Jan 21, 2026Phase 3 study in OverweightNCT07357766 · United States, Bulgaria, Denmark and more
  8. Jan 21, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07357740 · United States, Denmark, Greece and more
  9. Apr 7, 20263 phase 1 studiesNCT07527195, NCT07597018, NCT07557953
  10. Apr 27, 2026Phase 3 study in ObesityNCT07564414 · 2,500 planned · United States, Argentina, Australia and more
  11. May 17, 20262 phase 1 studiesNCT07605052, NCT07607587
  12. Jul 30, 2026Phase 3 study in OverweightNCT07745504 · 285 planned · United States, Greece, Hungary and more
  13. Sep 8, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07817251 · 210 planned · United States
  14. Oct 30, 2026Phase 3 study in HypertensionNCT07919405 · 1,408 planned · United States, Argentina, Australia and more

Ahead

  1. Mar 1, 2027Primary completion: phase 3 study in ObesityNCT07011667
  2. Apr 13, 2027Primary completion: phase 1 study in OverweightNCT07557953
  3. May 11, 2027Primary completion: phase 3 study in ObesityNCT07220642
  4. May 12, 2027Primary completion: phase 3 study in OverweightNCT07220759

TargetBeta

“CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide and a GLP-1 receptor agonist, semaglutide.”company, read by Claude · source

Other programs on CALCR

ProgramCompanyFurthest phaseStudies
zenagamtideNovo Nordiskphase 335
petrelintideruleZealand Pharmaphase 311
ABBV-295AbbViephase 25
PF-08653945Pfizerphase 22
GUB014295AbbViephase 11
CagriSema ANovo Nordiskphase 11

Studies

All 50 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07919405Hypertension · United States, Argentina, Australia and more3Not yet recruitingJun 1, 20281,408
NCT07817251Diabetes Mellitus, Type 2 · United States3RecruitingJun 9, 2027210
NCT07745504Overweight · United States, Greece, Hungary and more3RecruitingMay 18, 2027285
NCT07607587Obesity · United States1RecruitingNov 19, 2027114
NCT07605052Overweight · United States1CompletedAug 19, 202650
NCT07564414Obesity · United States, Argentina, Australia and more3RecruitingFeb 23, 20282,500
NCT07557953Overweight · Germany1RecruitingApr 13, 2027120
NCT07597018Obesity · Germany1RecruitingMay 28, 2027234
NCT07527195Obesity · Denmark1RecruitingApr 28, 2028100
NCT07357766Overweight · United States, Bulgaria, Denmark and more3WithdrawnNov 29, 20270
NCT07357740Diabetes Mellitus, Type 2 · United States, Denmark, Greece and more2WithdrawnAug 25, 20270
NCT07282613Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3RecruitingSep 7, 202980
NCT07253285Overweight · United States, Australia, Austria and more3RecruitingMar 20, 2030460
NCT07220759Overweight · United States, Argentina, Canada and more3Active, not recruitingMay 12, 2027330
NCT07220642Obesity · United States, Argentina, Australia and more3Active, not recruitingMay 11, 2027300
NCT07184086Obesity · United States1Active, not recruitingOct 12, 202780
NCT07011667Obesity · United States3Active, not recruitingMar 1, 2027609
NCT07010432Obesity · Denmark1RecruitingMay 3, 2028144
NCT06797869Diabetes Mellitus, Type 2 · United States, Canada, Denmark and more2CompletedJun 26, 2026142
NCT06780449Obesity · United States, Belgium, Canada and more3Active, not recruitingAug 28, 2028400
NCT06716307Obesity · United States1CompletedMar 28, 202518
NCT06534411Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedJun 2, 20261,023
NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more2CompletedNov 21, 2025270
NCT06403761Diabetes Mellitus, Type 2 · Germany1CompletedDec 28, 2025158
NCT06388187Obesity · United States, Canada, France and more3CompletedApr 22, 2026300
NCT06323174Diabetes Mellitus, Type 2 · United States, China, Hungary and more3CompletedOct 1, 2025189
NCT06323161Diabetes Mellitus, Type 2 · United States, China, Japan and more3CompletedSep 9, 2025274
NCT06289504Obesity · Canada1CompletedOct 16, 202434
NCT06267092Overweight · Germany1CompletedApr 7, 2025164
NCT06221969Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedMar 4, 20261,024
NCT06207877Obesity · Germany1CompletedOct 16, 202462
NCT06131437Obesity · United States3CompletedDec 8, 2025809
NCT06131372Renal Insufficiency, Chronic · United States, Argentina, Brazil and more2CompletedSep 24, 2025626
NCT06065540Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3CompletedNov 19, 20252,734
NCT05996848Obesity · China3CompletedJan 6, 2025300
NCT05813925Obesity · Japan, Taiwan3CompletedJan 17, 2025331
NCT05804162Obesity · Germany1CompletedAug 12, 2023107
NCT05669755Cardiovascular Diseases · United States, Argentina, Australia and more3Active, not recruitingSep 1, 20277,101
NCT05567796Obesity · United States, Argentina, Australia and more3Active, not recruitingOct 30, 20243,400
NCT05564104Hepatic Impairment · Czechia, Germany, Slovakia1CompletedSep 6, 202432
NCT05394519Overweight · United States, Austria, Canada and more3CompletedJan 28, 20251,200
NCT04982575Diabetes Mellitus, Type 2 · United States2CompletedJul 7, 202292
NCT04940078Obesity · Canada, Denmark1CompletedJan 19, 202240
NCT04209049Overweight · United States1CompletedJan 5, 202133
NCT04074174Overweight · Canada1CompletedMar 6, 202031
NCT03856047Overweight · United States, Canada, Denmark and more2CompletedMar 2, 2020706
NCT03787225Obesity · United States1CompletedJun 4, 201966
NCT03600480Obesity · United States1CompletedJun 12, 202096
NCT02958085Nutrition Disorders · United States1CompletedJan 24, 201896
NCT02300844Nutrition Disorders · United States1CompletedMar 21, 201654

How it is read

Names in the registry

  • “Cagrilintide”, 29 entries
  • “NNC0174-0833”, 7 entries
  • “CagriSema”, 3 entries
  • “CagriSema (Cagrilintide B and Semaglutide I)”, 3 entries
  • “Cagrisema”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.